Zusammenfassung
Weltweit entwickeln ca. 1/2 Million Frauen ein Zervixkarzinom.Die Inzidenz ist in sogenannten Entwicklungsländern drei Mal höher als in Ländern, in denen eine Krebsfrüherkennung betrieben wird. Die ursächliche Beziehung zwischen der Infektion durch sogenannte high-risk (HR) Typen humaner Papillomviren (HPV 16, 18 und andere) und Zervixkarzinom gilt als gesichert.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bosch FX, Rohan T, Schneider A, Frazer I, Pfister H, Castellsague X, Puig Tintore LM, Munoz N, zur HH (2001) Papillomavirus Research: Updating results to the year 2000. Highlights of the HPV 2000 International Papillomavirus conference. J Clin Pathol 54: 0–13
de Roda Husman AM, Walboomers JMM, van den Brule AJC, Meijer CLJM, Snijders PJF (1995) The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76:1057–1062
Elfgren K, Bistoletti P, Dillner L, Walboomers JM, Meijer CJ, Dillner J (1996) Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 174:937–942
Goldstone, SE, Neefe JR, Winnett MT, Palefsky JM (2001 ) HSPE7 treatment of high grade anal dysplasia: Updated results of an ongoing open label trial. 19th International Papillomavirus Conference, Florianapolis (Brazil), Ludwig Institute for Cancer Research, p 68
Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ (2000) Improved amplification of genital human papillomaviruses. J Clin Microbiol 38(1): 357–361
Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR (2001) Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine. J Natl Cancer Inst 93: 284–292
Hillemanns P (1999) Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet
Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, Melbye M, Adami HO, Gyllensten UB (2000) Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355: 2189–2193
Kim JJ, Wright TC, Goldie SJ (2002) Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287: 2382–2390
Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer P, von Knebel-Doeberitz M (1999) Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 59:6132–6136
Knutson KL (2001) Technology evaluation: T-cell activator,Xenova. Curr Opin Mol Ther 3:585–588
Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287:2372–2381
Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh NJ, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA (1999) Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 281: 1605–1610
Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM (1989) The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7: 209–214
Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6: 3406–3416
Nindl I, Rindfleisch K, Lotz B, Schneider A, Durst M (1999) Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer 82: 203–207
Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, Rozendaal L, Remmink AJ, Risse EKJ, van der Linden HC, Voorhorst F J, Kenemans P, Meijer CJLM (1999) Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354: 20–25
Peyton CL, Schiffman M, Lörincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morea LA, Rodriguez AC, Herrero R, Sherman ME, Wheeler CM (1998) Comparison of PCR-and Hybrid Capture-Based Human Papillomavirus Detection Systems Using Multiple Cervical Specimen Collection Strategies. J Clin Microbiol 36: 3248–3254
Ratnam S, Franco EL, Ferenczy A (2000) Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 9: 945–951
Schneider A, Hoyer H, Lotz B, Leistritz S, Kühne-Heid R, Nindl I, Müller B, Haerting J, Dürst M (2000) Screening for high grade cervical intraepithelial neoplasia and cancer by testing for high risk HPV, routine cytology or colposcopy. Int J Cancer 89: 529–534
Schneider A (1994) Natural history of genital papillomavirus infections. Intervirology 37:201–214
Solomon D, Schiffman M, Tarone R (2001) Comparison of Three Management Strategies for Patients With Atypical Squamous Cells of Undetermined Significance: Baseline Results From a Randomized Trial. J Natl Cancer Inst 93: 293–299
Wright-TC J, Denny L, Kuhn L, Pollack A, Lorincz A (2000) HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283: 81–86
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schneider, A., Gissmann, L. (2003). HPV Diagnostik als Voraussetzung zu neuen Präventions-und Therapiekonzepten beim Zervixkarzinom. In: Bender, H.G., Dall, P. (eds) 54. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18257-0_27
Download citation
DOI: https://doi.org/10.1007/978-3-642-18257-0_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62125-3
Online ISBN: 978-3-642-18257-0
eBook Packages: Springer Book Archive